Goldman Sachs’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Goldman Sachs’s Portfolio OCRX Stock Details OCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,193	Closed	-$42K	–	7176
2016 Q4	$42K	Buy	+20,193	New	+$47.1K	﹤0.01%	6441

Other funds holding OCRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's OCRX Position: Q1 2017 in Review

Goldman Sachs sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2017, closing a stake of 20,193 shares — an estimated $42K sold.

Goldman Sachs first reported a position in OCRX in Q4 2016 and held it in 1 quarter. The position peaked at $42K in Q4 2016. 26 funds tracked by Wall St. Rank hold OCRX as of Q1 2017.

Goldman Sachs reported no remaining Ocera Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Goldman Sachs sold 20,193 Ocera Therapeutics, Inc. shares in Q1 2017, an estimated $42K.
Goldman Sachs first reported a position in Ocera Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
Goldman Sachs's Ocera Therapeutics, Inc. position peaked at $42K in Q4 2016.
26 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.